195 related articles for article (PubMed ID: 36581998)
21. LncRNA GATA3-AS1 facilitates tumour progression and immune escape in triple-negative breast cancer through destabilization of GATA3 but stabilization of PD-L1.
Zhang M; Wang N; Song P; Fu Y; Ren Y; Li Z; Wang J
Cell Prolif; 2020 Sep; 53(9):e12855. PubMed ID: 32687248
[TBL] [Abstract][Full Text] [Related]
22. PD-L1 tumor-intrinsic signaling and its therapeutic implication in triple-negative breast cancer.
Chen C; Li S; Xue J; Qi M; Liu X; Huang Y; Hu J; Dong H; Ling K
JCI Insight; 2021 Apr; 6(8):. PubMed ID: 33884962
[TBL] [Abstract][Full Text] [Related]
23. Taraxacum mongolicum extract inhibited malignant phenotype of triple-negative breast cancer cells in tumor-associated macrophages microenvironment through suppressing IL-10 / STAT3 / PD-L1 signaling pathways.
Deng XX; Jiao YN; Hao HF; Xue D; Bai CC; Han SY
J Ethnopharmacol; 2021 Jun; 274():113978. PubMed ID: 33716082
[TBL] [Abstract][Full Text] [Related]
24. ACADL suppresses PD-L1 expression to prevent cancer immune evasion by targeting Hippo/YAP signaling in lung adenocarcinoma.
Li L; Wang LL; Wang TL; Zheng FM
Med Oncol; 2023 Mar; 40(4):118. PubMed ID: 36929466
[TBL] [Abstract][Full Text] [Related]
25. PD-1 Independent Role of PD-L1 in Triple-Negative Breast Cancer Progression.
Alkaabi D; Arafat K; Sulaiman S; Al-Azawi AM; Attoub S
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047395
[TBL] [Abstract][Full Text] [Related]
26. β, β-Dimethylacrylshikonin potentiates paclitaxel activity, suppresses immune evasion and triple negative breast cancer progression via STAT3Y705 phosphorylation inhibition based on network pharmacology and transcriptomics analysis.
Wu Z; Wu H; Wang Z; Li H; Gu H; Xia E; Yan C; Dai Y; Liu C; Wang X; Lv L; Bao J; Wang O; Dai X
Phytomedicine; 2023 Jun; 114():154769. PubMed ID: 36940580
[TBL] [Abstract][Full Text] [Related]
27. The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1.
Janse van Rensburg HJ; Azad T; Ling M; Hao Y; Snetsinger B; Khanal P; Minassian LM; Graham CH; Rauh MJ; Yang X
Cancer Res; 2018 Mar; 78(6):1457-1470. PubMed ID: 29339539
[TBL] [Abstract][Full Text] [Related]
28. WBP2 Downregulation Inhibits Proliferation by Blocking YAP Transcription and the EGFR/PI3K/Akt Signaling Pathway in Triple Negative Breast Cancer.
Song H; Wu T; Xie D; Li D; Hua K; Hu J; Fang L
Cell Physiol Biochem; 2018; 48(5):1968-1982. PubMed ID: 30092563
[TBL] [Abstract][Full Text] [Related]
29. D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1.
Zhang R; Yang Y; Dong W; Lin M; He J; Zhang X; Tian T; Yang Y; Chen K; Lei QY; Zhang S; Xu Y; Lv L
Proc Natl Acad Sci U S A; 2022 Feb; 119(8):. PubMed ID: 35181605
[TBL] [Abstract][Full Text] [Related]
30. PDL1 And LDHA act as ceRNAs in triple negative breast cancer by regulating miR-34a.
Huang X; Xie X; Wang H; Xiao X; Yang L; Tian Z; Guo X; Zhang L; Tang H; Xie X
J Exp Clin Cancer Res; 2017 Sep; 36(1):129. PubMed ID: 28915924
[TBL] [Abstract][Full Text] [Related]
31. Inhibitors of PD-1/PD-L1 and ERK1/2 impede the proliferation of receptor positive and triple-negative breast cancer cell lines.
Bräutigam K; Kabore-Wolff E; Hussain AF; Polack S; Rody A; Hanker L; Köster F
J Cancer Res Clin Oncol; 2021 Oct; 147(10):2923-2933. PubMed ID: 34185141
[TBL] [Abstract][Full Text] [Related]
32. Focal Adhesion Kinase (FAK)-Hippo/YAP transduction signaling mediates the stimulatory effects exerted by S100A8/A9-RAGE system in triple-negative breast cancer (TNBC).
Rigiracciolo DC; Nohata N; Lappano R; Cirillo F; Talia M; Adame-Garcia SR; Arang N; Lubrano S; De Francesco EM; Belfiore A; Gutkind JS; Maggiolini M
J Exp Clin Cancer Res; 2022 Jun; 41(1):193. PubMed ID: 35655319
[TBL] [Abstract][Full Text] [Related]
33. Atypical ubiquitin ligase RNF31: the nuclear factor modulator in breast cancer progression.
Zhu J; Zhuang T; Yang H; Li X; Liu H; Wang H
BMC Cancer; 2016 Jul; 16():538. PubMed ID: 27460922
[TBL] [Abstract][Full Text] [Related]
34. Luteolin suppresses epithelial-mesenchymal transition and migration of triple-negative breast cancer cells by inhibiting YAP/TAZ activity.
Cao D; Zhu GY; Lu Y; Yang A; Chen D; Huang HJ; Peng SX; Chen LW; Li YW
Biomed Pharmacother; 2020 Sep; 129():110462. PubMed ID: 32768952
[TBL] [Abstract][Full Text] [Related]
35. IGF-1/IGF-1R/FAK/YAP Transduction Signaling Prompts Growth Effects in Triple-Negative Breast Cancer (TNBC) Cells.
Rigiracciolo DC; Nohata N; Lappano R; Cirillo F; Talia M; Scordamaglia D; Gutkind JS; Maggiolini M
Cells; 2020 Apr; 9(4):. PubMed ID: 32325700
[TBL] [Abstract][Full Text] [Related]
36. CircNR3C2 promotes HRD1-mediated tumor-suppressive effect via sponging miR-513a-3p in triple-negative breast cancer.
Fan Y; Wang J; Jin W; Sun Y; Xu Y; Wang Y; Liang X; Su D
Mol Cancer; 2021 Feb; 20(1):25. PubMed ID: 33530981
[TBL] [Abstract][Full Text] [Related]
37. Ring finger protein 31-mediated atypical ubiquitination stabilizes forkhead box P3 and thereby stimulates regulatory T-cell function.
Zhu F; Yi G; Liu X; Zhu F; Zhao A; Wang A; Zhu R; Chen Z; Zhao B; Fang S; Yu X; Lin R; Liang R; Li D; Zhao W; Zhang Z; Guo W; Zhang S; Ge S; Fan X; Zhao G; Li B
J Biol Chem; 2018 Dec; 293(52):20099-20111. PubMed ID: 30389786
[TBL] [Abstract][Full Text] [Related]
38. Expression of PD-L1 Attenuates the Positive Impacts of High-level Tumor-infiltrating Lymphocytes on Prognosis of Triple-negative Breast Cancer.
Zhu X; Zhang Q; Wang D; Liu C; Han B; Yang JM
Cancer Biol Ther; 2019; 20(8):1105-1112. PubMed ID: 30929569
[No Abstract] [Full Text] [Related]
39. Disruption of RBMS3 suppresses PD-L1 and enhances antitumor immune activities and therapeutic effects of auranofin against triple-negative breast cancer.
Zhou Y; Liang Z; Xia Y; Li S; Liang J; Hu Z; Tang C; Zhao Q; Gong Q; Ouyang Y
Chem Biol Interact; 2023 Jan; 369():110260. PubMed ID: 36414028
[TBL] [Abstract][Full Text] [Related]
40. YAP-Induced PD-L1 Expression Drives Immune Evasion in BRAFi-Resistant Melanoma.
Kim MH; Kim CG; Kim SK; Shin SJ; Choe EA; Park SH; Shin EC; Kim J
Cancer Immunol Res; 2018 Mar; 6(3):255-266. PubMed ID: 29382670
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
